{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:01:04Z","timestamp":1775570464614,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"DOI":"10.7759\/cureus.103280","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:19:11Z","timestamp":1770650351000},"source":"Crossref","is-referenced-by-count":1,"title":["Enteropathogenic Escherichia coli and Bacterial Overgrowth Co-infection Exacerbating Immune Checkpoint Inhibitor-Induced Colitis"],"prefix":"10.7759","author":[{"given":"Ermias A","family":"Kibru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul-Rahaman A","family":"Ottun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John  G","family":"Dusek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice","family":"Hama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bezawit M","family":"Fikadu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref3","article-title":"Enteropathogenic Escherichia coli\u2014a summary of the literature","volume":"12","author":"Mare AD","year":"2021","unstructured":"Mare AD, Ciurea CN, Man A, Tudor B, Moldovan V, Decean L, Toma F. Enteropathogenic Escherichia coli\u2014a summary of the literature. Gastroenterol Insights. 2021, 12:28-40.","journal-title":"Gastroenterol Insights"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006706","article-title":"Attaching and effacing (A\/E) lesion formation by enteropathogenic E. coli on human intestinal mucosa is dependent on non-LEE effectors","volume":"13","author":"Cepeda-Molero M","year":"2017","unstructured":"Cepeda-Molero M, Berger CN, Walsham AD, et al.. Attaching and effacing (A\/E) lesion formation by enteropathogenic E. coli on human intestinal mucosa is dependent on non-LEE effectors. PLoS Pathog. 2017, 13:e1006706. 10.1371\/journal.ppat.1006706","journal-title":"PLoS Pathog"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang Y","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al.. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018, 6:37. 10.1186\/s40425-018-0346-6","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2024.003","article-title":"Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events","volume":"57","author":"Kim MK","year":"2024","unstructured":"Kim MK, Hwang SW. Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events. Clin Endosc. 2024, 57:725-34. 10.5946\/ce.2024.003","journal-title":"Clin Endosc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.33","article-title":"Metabolic acidosis: pathophysiology, diagnosis and management","volume":"6","author":"Kraut JA","year":"2010","unstructured":"Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010, 6:274-85. 10.1038\/nrneph.2010.33","journal-title":"Nat Rev Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000501","article-title":"ACG clinical guideline: small intestinal bacterial overgrowth","volume":"115","author":"Pimentel M","year":"2020","unstructured":"Pimentel M, Saad RJ, Long MD, Rao SS. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020, 115:165-78. 10.14309\/ajg.0000000000000501","journal-title":"Am J Gastroenterol"},{"key":"ref9","unstructured":"Centers for Disease Control and Prevention. Information for clinicians. E. coli infection. (2024). Accessed: December 20, 2025: https:\/\/www.cdc.gov\/ecoli\/about\/index.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix669","article-title":"2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea","volume":"65","author":"Shane AL","year":"2017","unstructured":"Shane AL, Mody RK, Crump JA, et al.. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017, 65:e45-80. 10.1093\/cid\/cix669","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458330-enteropathogenic-escherichia-coli-and-bacterial-overgrowth-co-infection-exacerbating-immune-checkpoint-inhibitor-induced-colitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:19:12Z","timestamp":1770650352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458330-enteropathogenic-escherichia-coli-and-bacterial-overgrowth-co-infection-exacerbating-immune-checkpoint-inhibitor-induced-colitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.103280","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}